Chemoinformaics analysis of (-)-(7R,9R,11R-7-N-METHYL-11(PROP-2-ENYL)CYTISINE
| Molecular Weight | 190.246 | nRot | 0 |
| Heavy Atom Molecular Weight | 176.134 | nRig | 16 |
| Exact Molecular Weight | 190.111 | nRing | 3 |
| Solubility: LogS | 0.63 | nHRing | 3 |
| Solubility: LogP | 0.508 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 28 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 14 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 2 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 11 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 6 |
| nHA | 3 | APOL | 30.7071 |
| nHD | 1 | BPOL | 17.1929 |
| QED | 0.648 |
| Synth | 4.046 |
| Natural Product Likeliness | -0.211 |
| NR-PPAR-gamma | 0.007 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.002 |
| HIA | 0.01 |
| CACO-2 | -4.815 |
| MDCK | 0.00000382 |
| BBB | 0.96 |
| PPB | 0.170383 |
| VDSS | 1.98 |
| FU | 0.796488 |
| CYP1A2-inh | 0.063 |
| CYP1A2-sub | 0.266 |
| CYP2c19-inh | 0.04 |
| CYP2c19-sub | 0.743 |
| CYP2c9-inh | 0.006 |
| CYP2c9-sub | 0.098 |
| CYP2d6-inh | 0.677 |
| CYP2d6-sub | 0.716 |
| CYP3a4-inh | 0.06 |
| CYP3a4-sub | 0.331 |
| CL | 7.092 |
| T12 | 0.319 |
| hERG | 0.137 |
| Ames | 0.752 |
| ROA | 0.825 |
| SkinSen | 0.223 |
| Carcinogencity | 0.595 |
| EI | 0.04 |
| Respiratory | 0.81 |
| NR-Aromatase | 0.002 |
| Antiviral | No |
| Prediction | 0.715532 |